Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmunityBio ( (IBRX) ) has shared an update.
On March 30, 2026, ImmunityBio amended its Revenue Interest Purchase Agreement with Oberland Capital, securing an additional $75 million in non-dilutive financing that lifts total committed capital under the structure to $375 million. In exchange, investors’ revenue interest on global product net sales outside China and related territories rises to a higher tiered range, with future reset mechanisms and a cap tied to 195% of cumulative purchaser payments, while the funding is secured by substantially all company and guarantor subsidiary assets and earmarked for general corporate purposes.
Concurrent with the amendment closing on March 30, 2026, Nant Capital, an affiliate of Executive Chairman Patrick Soon-Shiong, converted $25 million of principal under a large convertible promissory note into about 4.6 million ImmunityBio common shares, reducing the note’s remaining principal to $480 million. Together, the non-dilutive royalty financing and insider debt-to-equity conversion, formally announced on March 31, 2026, strengthen ImmunityBio’s balance sheet to support global commercial expansion following recent ANKTIVA approvals and the continued advancement of its broader immunotherapy pipeline.
The most recent analyst rating on (IBRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
The score is held back primarily by weak financial durability (negative equity, large losses, and sustained cash burn), partially offset by strong commercial/regulatory traction for ANKTIVA and a mixed but improving longer-term technical trend. Valuation provides limited support given continued losses and no dividend.
To see Spark’s full report on IBRX stock, click here.
More about ImmunityBio
ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing next-generation immunotherapies that activate the patient’s immune system against cancer and infectious diseases. Its platform centers on the IL-15 receptor superagonist ANKTIVA and includes adenovirus-vectored vaccines, NK-cell therapies, and other immunomodulators aimed at durable immune responses and reduced reliance on high-dose chemo-radiation.
The company is a vertically integrated, commercial-stage immunotherapy player with a global footprint for ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer. Since the initial U.S. FDA approval in April 2024, ANKTIVA has gained authorizations across about 34 countries, including the United Kingdom, the European Union, Saudi Arabia, and Macau, underscoring rapid international expansion and a growing commercial base.
Average Trading Volume: 39,315,387
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.85B
Learn more about IBRX stock on TipRanks’ Stock Analysis page.